An Extension Multicenter Phase II Open Label Non-Comparative Trial of RP56976 Administered Every Three Weeks in Combination With Daily Prednisolone for Metastatic Hormone Refractory Prostate Cancer.

Trial Profile

An Extension Multicenter Phase II Open Label Non-Comparative Trial of RP56976 Administered Every Three Weeks in Combination With Daily Prednisolone for Metastatic Hormone Refractory Prostate Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2015

At a glance

  • Drugs Docetaxel (Primary) ; Prednisolone
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 20 May 2009 Actual patient number (16) added as reported by ClinicalTrials.gov.
    • 16 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top